AR066458A1 - Derivados de piperidina, procesos de obtencion y composiciones farmaceuticas. - Google Patents
Derivados de piperidina, procesos de obtencion y composiciones farmaceuticas.Info
- Publication number
- AR066458A1 AR066458A1 ARP080101913A ARP080101913A AR066458A1 AR 066458 A1 AR066458 A1 AR 066458A1 AR P080101913 A ARP080101913 A AR P080101913A AR P080101913 A ARP080101913 A AR P080101913A AR 066458 A1 AR066458 A1 AR 066458A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkylene
- carbocyclic group
- group
- members
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 24
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 20
- 125000002947 alkylene group Chemical group 0.000 abstract 18
- 125000003118 aryl group Chemical group 0.000 abstract 15
- 125000000623 heterocyclic group Chemical group 0.000 abstract 15
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical class 0.000 abstract 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- -1 amino- (hydroxy) Chemical class 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000005243 carbonyl alkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicacion 1: Un compuesto de la formula (1), o tautomeros, o estereoisomeros, o solvatos, o sales farmacéuticamente aceptables de los mismos, en donde: M1 y M2 son independientemente formula (2); R1, R2, R3, y R4 se seleccionanindependientemente a partir de H, alquilo C1-8, alquilo C1-8-carboxilo, halo-alquilo C1-8, grupo carbocíclico C3-15, alquilo C1-8, alcoxilo C1-8-carbonilo, un grupo carbocíclico aromático de 6 a 15 miembros, un grupo heterocíclico C4-14, un alquiloC1-8 sustituido por un grupo heterocíclico de 4 a 14 miembros, y un alquilo C1-8 sustituido por un grupo carbocíclico aromático de 6 a 15 miembros, o R1 y R2, con el átomo de nitrogeno con el que están unidos, forman un grupo heterocíclico de 3 a 14miembros opcionalmente sustituido por R14, o R3 y R4, con el átomo de nitrogeno con el que están unidos, forman un grupo heterocíclico de 3 a 14 miembros, opcionalmente sustituido por R14; L1 y L2 se seleccionan independientemente a partir deformulas (3) y (4), R6, R5, y R5a se seleccionan independientemente a partir de H, alquilo C1-8, alquilo C1-8-carboxilo, alquilo C1-8-alcoxilo, halo-alquilo C1-8, grupo carbocíclico C3-15, alquilo C1-8-carbonilo, alcoxilo C1-8-carbonilo, nitro,ciano, un grupo carbocíclico aromático de 6 a 15 miembros, un grupo heterocíclico de 4 a 14 miembros, un alquilo C1-8 sustituido por un grupo heterocíclico C4-14 y un alquilo C1-8 sustituido por un grupo carbocíclico aromático de 6 a 15 miembros; W1y W2 se seleccionan independientemente a partir de alquileno C0-8; X1 y X2 se seleccionan independientemente a partir de un grupo heterocíclico C4-14 miembros; Y1 y Y2 son independientemente -alquileno C0-8; o alquilo C1-8-amino; A se selecciona apartir de un grupo carbocíclico aromático de 6 a 15 miembros, -CONR11a-(alquileno C1-8)-NR11aCO-, -CO-(alquileno C1-8)CO-, -CO-(alquenileno C1-8)-CO-, -C(=O), -CO-(alquileno C0-8)-Z-(alquileno C0-8)-CO-, -CONR11a(alquileno C0-8)-Z-(alquileno C0-8)-NR11aCO, grupo 10 carbocíclico C3-15, y un grupo heterocíclico de 4 a 14 miembros; Z se selecciona a partir de un grupo carbocíclico aromático de 6 a 15 miembros, grupo carbocíclico de 3 a 15 miembros, y un grupo heterocíclico de 4 a 14 miembros; Tse selecciona a partir de H, halogeno, alquilo C1-8, halo-alquilo C1-8, haloalcoxilo C1-8, grupo carbocíclico C3-15, nitro, ciano, un grupo carbocíclico aromático C6-15 y un alquilo C1-8 sustituido por un grupo carbocíclico aromático de 6 a 15miembros; en donde cada grupo carbocíclico aromático de 6 a 15 miembros, y cada grupo heterocíclico de 4 a 14 miembros o cada grupo heterocíclico de 5 a 14 miembros, a menos que se especifique de otra, está independientemente opcionalmentesustituido por uno o más grupos seleccionados a partir de OH, alcoxilo C1-8, alquilo C1-8, halogeno, SO2NR11R12, hidroxi-alcoxilo C1-8 opcionalmente sustituido por hidroxilo, (alquileno C0-4)-CONR11R12, (alquileno C0-4)-N=C(NR11R12)2, -O-(alquilenoC1-4)-N=C(NR11R12)2, -O-(alquileno C1-4)-CONR11R12, aralcoxilo C7-10, aralquilo C7-10, SH, S-(alquileno C1-8), SO2-(alquileno C1-8), SO-(alquileno C1-8), NR11R12, NR11-(grupo carbocíclico C3-12), en donde el grupo carbocíclico está opcionalmentesustituido por halogeno o alquilo C1-8, R15, un alquilo C1-8 sustituido por R15, R16, un alquilo C1-8 sustituido por R16, O-(alquileno C1-8)-NR11-(C=O)O-(alquileno C0-4)-R15, ciano, oxo, carboxilo, nitro, alquilo C1-8-carbonilo, hidroxi-alquilo C1-8, halo-alquilo C1-8, amino-alquilo C1-8, amino-(hidroxi)-alquilo C1-8, y alcoxilo C1-8 opcionalmente sustituido por amino-carbonilo, en donde R15 es un grupo carbocíclico aromático de 6 a 15 miembros, opcionalmente sustituido por OH, alcoxilo C1-8,alquilo C1-8, halogeno, y halo-alquilo C1-8, R16 es un grupo heterocíclico de 4 a 14 miembros, opcionalmente sustituido por OH, alcoxilo C1-8, alquilo C1-8, grupo carbocíclico aromático de 6 a 15 miembros, CO2H, (C=O)-grupo heterocíclico de 3 a 14miembros, halogeno, y halo-alquilo C1-8, y en donde cada grupo alquileno, a menos que se especifique de otra manera, está opcionalmente sustituido por alquilo C1-8, halogeno, alcoxilo C1-8, carboxilo, alquilo C1-8-carboxilo, halo-alquilo C1-8, halo-alcoxilo C1-8, grupo carbocíclico C3-15, alquilo C1-8-carbonilo, alcoxilo C1-8-carbonilo, nitro, ciano, R15, un alquilo C1-8 sustituido por R15, R16, o un alquilo C1-8 sustituido por R16; cada R11 y R12 se seleccionan independientemente a partir deH, alquilo C1-8, halo-alquilo C1-8, grupo carbocíclico C3-15, grupo carbocíclico aromático C6-15, y un grupo heterocíclico de 4 a 14 miembros opcionalmente sustituido por -COOH o por alquilo C1-8, o R11 y R12, junto con el átomo de nitrogeno con elque están unidos, forman un grupo heterocíclico de 5 a 14 miembros opcionalmente sustituido por CO2H, alquilo C1-8, (C=O)-grupo heterocíclico de 4 a 14 miembros, o un grupo carbocíclico aromático de 6 a 15 miembros, cuando R11 o R12 son alquilo C1-8, pueden estar opcionalmente mono- o di-sustituidos por grupo carbocíclico aromático C61-5, grupo heterocíclico de 5 a 14 miembros, alquilo C1-8-amino, OH, o un di-(alquilo C1-8)-amino opcionalmente sustituido por OH; R11a se selecciona a partir deH y alquilo C1-8; y R14 se selecciona a partir de H, halogeno, alquilo C1-8, OH, grupo carbocíclico aromático de 6 a 15 miembros, aralquilo C7-14, y O-aralquilo C7-14.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07107654 | 2007-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066458A1 true AR066458A1 (es) | 2009-08-19 |
Family
ID=38581916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101913A AR066458A1 (es) | 2007-05-07 | 2008-05-06 | Derivados de piperidina, procesos de obtencion y composiciones farmaceuticas. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8318935B2 (es) |
| EP (2) | EP2332933A1 (es) |
| JP (1) | JP5244904B2 (es) |
| KR (1) | KR20100005730A (es) |
| CN (1) | CN101687851B (es) |
| AR (1) | AR066458A1 (es) |
| AT (1) | ATE499363T1 (es) |
| AU (1) | AU2008248598B2 (es) |
| BR (1) | BRPI0811562A2 (es) |
| CA (1) | CA2685546A1 (es) |
| CL (1) | CL2008001301A1 (es) |
| CO (1) | CO6290667A2 (es) |
| CR (1) | CR11091A (es) |
| DE (1) | DE602008005140D1 (es) |
| EA (1) | EA200901489A1 (es) |
| EC (1) | ECSP099718A (es) |
| ES (1) | ES2361595T3 (es) |
| GT (1) | GT200900289A (es) |
| HN (1) | HN2009003214A (es) |
| IL (1) | IL201828A0 (es) |
| MA (1) | MA31400B1 (es) |
| MX (1) | MX2009012077A (es) |
| NZ (1) | NZ580737A (es) |
| PE (1) | PE20090733A1 (es) |
| PL (1) | PL2155721T3 (es) |
| PT (1) | PT2155721E (es) |
| SV (1) | SV2009003406A (es) |
| TN (1) | TN2009000469A1 (es) |
| TW (1) | TWI351402B (es) |
| WO (1) | WO2008135557A1 (es) |
| ZA (1) | ZA200907491B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| KR101654549B1 (ko) | 2008-02-26 | 2016-09-07 | 패리온 사이언스 인코퍼레이티드 | 다중방향족 나트륨 채널 차단제 |
| KR20110085768A (ko) | 2010-01-21 | 2011-07-27 | 삼성전자주식회사 | Ｃｍｏｓ 이미지 센서, 상기 이미지 센서의 데이터 리드아웃 방법, 및 상기 이미지 센서를 포함하는 전자 시스템 |
| US9050339B2 (en) | 2010-09-17 | 2015-06-09 | Novartis Ag | Pyrazine derivatives as ENaC blockers |
| US8372845B2 (en) * | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| EP2773624A1 (en) * | 2011-11-02 | 2014-09-10 | Boehringer Ingelheim International GmbH | Novel process for the preparation of acylguanidines and acylthioureas |
| ES2645744T3 (es) * | 2011-11-02 | 2017-12-07 | Boehringer Ingelheim International Gmbh | Compuestos heterocíclicos, medicamentos que contienen dichos compuestos, uso de los mismos y procedimientos para la preparación de los mismos |
| US8859559B2 (en) * | 2011-12-20 | 2014-10-14 | Boehringer Ingelheim International Gmbh | Substituted pyrazines and their use in the treatment of disease |
| CN104520321A (zh) | 2012-01-09 | 2015-04-15 | 斯克利普斯研究所 | 超长互补决定区及其用途 |
| WO2013174757A1 (en) | 2012-05-25 | 2013-11-28 | Boehringer Ingelheim International Gmbh | Tertiary amines, medicaments containing said amines, use thereof and processes for the preparation thereof |
| JP6072920B2 (ja) * | 2012-09-24 | 2017-02-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 複素環化合物、前記化合物を含む薬物、これらの使用及びこれらの調製方法 |
| EP3470063B1 (en) | 2012-11-02 | 2025-01-01 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cftr mediated diseases |
| JP6392242B2 (ja) | 2012-12-17 | 2018-09-19 | パリオン・サイエンシィズ・インコーポレーテッド | 粘膜への水分付与が不十分であることが好都合である疾患の治療に有用なクロロ−ピラジンカルボキサミド誘導体 |
| MX2015007797A (es) | 2012-12-17 | 2015-10-05 | Parion Sciences Inc | Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida. |
| JP6353032B2 (ja) * | 2013-04-30 | 2018-07-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ジアミノピラジン化合物、前記化合物を含有する医薬、その使用、およびその調製方法 |
| KR20160054460A (ko) * | 2013-07-02 | 2016-05-16 | 더 캘리포니아 인스티튜트 포 바이오메디칼 리써치 | 낭성 섬유증의 치료를 위한 화합물 |
| US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
| UY36034A (es) | 2014-03-18 | 2015-09-30 | Astrazeneca Ab | Derivados de 3,5-diamino-6-cloro-pirazina-2-carboxamida y sales farmaceuticamente aceptables de estos |
| CN106102724A (zh) | 2014-03-27 | 2016-11-09 | 诺华股份有限公司 | 用于吸入活性药物成分的经喷雾干燥的水包油包固体分散系 |
| GB201412545D0 (en) * | 2014-07-15 | 2014-08-27 | Univ Manchester The And Manchester Metropolitan University | Enzymatic processes and uses |
| WO2016112120A1 (en) * | 2015-01-07 | 2016-07-14 | The California Institute For Biomedical Research | Compounds for treatment of cystic fibrosis |
| EP3245202B1 (en) * | 2015-01-12 | 2020-03-11 | Boehringer Ingelheim International GmbH | Tetrasubstituted benzimidazolium compounds useful in the treatment of respiratory diseases |
| US10155749B2 (en) * | 2015-01-12 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Substituted benzimidazolium compounds useful in the treatment of respiratory diseases |
| US9932324B2 (en) * | 2015-01-12 | 2018-04-03 | Boehringer Ingelheim International Gmbh | Substituted benzimidazolium compounds useful in the treatment of respiratory diseases |
| US10291868B2 (en) * | 2016-01-29 | 2019-05-14 | SK Hynix Inc. | Image sensing device |
| GB201610854D0 (en) | 2016-06-21 | 2016-08-03 | Entpr Therapeutics Ltd | Compounds |
| GB201619694D0 (en) | 2016-11-22 | 2017-01-04 | Entpr Therapeutics Ltd | Compounds |
| EP3600440A1 (en) | 2017-03-20 | 2020-02-05 | Sienna Biopharmaceuticals, Inc. | Reduced exposure conjugates modulating therapeutic targets |
| WO2018175302A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugates targeting c-src with reduced exposure |
| GB201717051D0 (en) | 2017-10-17 | 2017-11-29 | Enterprise Therapeutics Ltd | Compounds |
| GB201808093D0 (en) | 2018-05-18 | 2018-07-04 | Enterprise Therapeutics Ltd | Compounds |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1219606A (en) | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
| US3544571A (en) | 1968-09-04 | 1970-12-01 | Merck & Co Inc | Process for making pyrazinoylthiourea compounds |
| US4246406A (en) | 1979-03-27 | 1981-01-20 | Merck & Co., Inc. | Heterocyclic substituted pyrazinoylguanidines |
| JPS6235216A (ja) | 1985-08-09 | 1987-02-16 | Noritoshi Nakabachi | 不均質物質層の層厚非破壊測定方法および装置 |
| GB8923590D0 (en) | 1989-10-19 | 1989-12-06 | Pfizer Ltd | Antimuscarinic bronchodilators |
| PT100441A (pt) | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
| WO1993018007A1 (fr) | 1992-03-13 | 1993-09-16 | Tokyo Tanabe Company Limited | Nouveau derive de carbostyrile |
| JP3192424B2 (ja) | 1992-04-02 | 2001-07-30 | スミスクライン・ビーチャム・コーポレイション | アレルギーまたは炎症疾患の治療用化合物 |
| CZ283425B6 (cs) | 1992-04-02 | 1998-04-15 | Smithkline Beecham Corporation | Fenylové deriváty a farmaceutické prostředky s jejich obsahem |
| AU3924993A (en) | 1992-04-02 | 1993-11-08 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
| TW394760B (en) * | 1993-09-07 | 2000-06-21 | Hoffmann La Roche | Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same |
| GB9622386D0 (en) | 1996-10-28 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| US6166037A (en) | 1997-08-28 | 2000-12-26 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
| WO1999016766A1 (en) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Benzodioxole derivatives |
| US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| DE69827673T2 (de) | 1998-06-30 | 2005-04-21 | Dow Global Technologies Inc | Polymerpolyole und ein verfahren zu ihrer darstellung |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| PL203117B1 (pl) | 1999-05-04 | 2009-08-31 | Schering Corp | Piperydynopiperydynowa pochodna użyteczna jako antagonista CCR5, zawierająca ją kompozycja farmaceutyczna i jej zastosowanie |
| HUP0202867A3 (en) | 1999-05-04 | 2004-01-28 | Schering Corp | Piperazine derivatives useful as ccr5 antagonists and pharmaceutical compositions containing them |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| ES2304352T3 (es) * | 1999-07-19 | 2008-10-16 | University Of North Carolina At Chapel Hill | Compuestos farmacologicamente activos con dos principios activos unidos covalentemente (bloqueante de los canales de sodio/agonista del receptor p2y2) para el tratamiento de superficies mucosas. |
| EP1671651B1 (en) | 1999-08-21 | 2009-11-11 | Nycomed GmbH | Synergistic combination of pumafentrine and salmeterol |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| AU5629301A (en) | 2000-04-27 | 2001-11-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Novel, slow-acting betamimetics, a method for their production and their use as medicaments |
| UA72632C2 (uk) | 2000-06-27 | 2005-03-15 | Лабораторіос С.А.Л.В.А.Т., С.А. | Карбамати, похідні від арилалкіламінів |
| GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| DE10038639A1 (de) | 2000-07-28 | 2002-02-21 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| WO2002012265A1 (en) | 2000-08-05 | 2002-02-14 | Glaxo Group Limited | 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYL) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| AU2002228015B2 (en) | 2000-12-22 | 2007-08-23 | Almirall, S.A. | Quinuclidine carbamate derivatives and their use as M3 antagonists |
| UA75626C2 (en) | 2000-12-28 | 2006-05-15 | Almirall Prodesfarma Ag | Quinuclidine derivatives and medicinal compositions containing the same |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| US7144908B2 (en) | 2001-03-08 | 2006-12-05 | Glaxo Group Limited | Agonists of beta-adrenoceptors |
| ES2296923T3 (es) | 2001-03-22 | 2008-05-01 | Glaxo Group Limited | Derivados formanilidas como agonistas del adrenorreceptor beta2. |
| US7291608B2 (en) | 2001-04-30 | 2007-11-06 | Glaxo Group Limited | Anti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α |
| JP2005500290A (ja) | 2001-06-12 | 2005-01-06 | グラクソ グループ リミテッド | 抗炎症性の、１７β−カルボチオアートアンドロスタン誘導体である１７α複素環エステル |
| JP4405258B2 (ja) | 2001-06-21 | 2010-01-27 | ヴェレニウム コーポレイション | ニトリラーゼ |
| ATE417606T1 (de) | 2001-09-14 | 2009-01-15 | Glaxo Group Ltd | Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege |
| KR20050030169A (ko) | 2001-10-17 | 2005-03-29 | 유씨비 소시에떼아노님 | 퀴누클리딘 유도체, 이의 제조 방법 및 ｍ2 및/또는 ｍ3무스카린 수용체 억제제로서의 이의 용도 |
| GB0125259D0 (en) | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
| MY130622A (en) | 2001-11-05 | 2007-07-31 | Novartis Ag | Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors |
| WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
| TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| WO2003048181A1 (en) | 2001-12-01 | 2003-06-12 | Glaxo Group Limited | 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents |
| UA76571C2 (en) | 2001-12-20 | 2006-08-15 | Derivatives of 1-alkyl-1-azoniabicyclo [2.2.2.]octanecarbamate and use thereof as antagonists of muscarin receptor | |
| WO2003072592A1 (en) | 2002-01-15 | 2003-09-04 | Glaxo Group Limited | 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents |
| WO2003062259A2 (en) | 2002-01-21 | 2003-07-31 | Glaxo Group Limited | Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents |
| GB0202216D0 (en) | 2002-01-31 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| PL373043A1 (en) | 2002-03-26 | 2005-08-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| CA2477764A1 (en) | 2002-03-26 | 2003-10-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| CA2481320A1 (en) | 2002-04-11 | 2003-10-23 | Merck & Co., Inc. | 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
| ES2206021B1 (es) | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
| JP2005523920A (ja) | 2002-04-25 | 2005-08-11 | グラクソ グループ リミテッド | フェネタノールアミン誘導体 |
| WO2003099764A1 (en) | 2002-05-28 | 2003-12-04 | Theravance, Inc. | ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS |
| US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| ES2201907B1 (es) | 2002-05-29 | 2005-06-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos. |
| DE10224888A1 (de) | 2002-06-05 | 2003-12-24 | Merck Patent Gmbh | Pyridazinderivate |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| DE10225574A1 (de) | 2002-06-10 | 2003-12-18 | Merck Patent Gmbh | Aryloxime |
| DE10227269A1 (de) | 2002-06-19 | 2004-01-08 | Merck Patent Gmbh | Thiazolderivate |
| EP1517895B1 (en) | 2002-06-25 | 2007-03-14 | Merck Frosst Canada Ltd. | 8-(biaryl) quinoline pde4 inhibitors |
| JP2005538972A (ja) | 2002-07-02 | 2005-12-22 | メルク フロスト カナダ アンド カンパニー | ジアリール置換エタンピリドンｐｄｅ４阻害剤 |
| ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
| MXPA05000345A (es) | 2002-07-08 | 2005-03-31 | Pfizer Prod Inc | Moduladores del receptor de glucocorticoides. |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| PE20050130A1 (es) | 2002-08-09 | 2005-03-29 | Novartis Ag | Compuestos organicos |
| EP1556369A1 (en) | 2002-08-10 | 2005-07-27 | ALTANA Pharma AG | Pyridazinone-derivatives as pde4 inhibitors |
| AU2003255376A1 (en) | 2002-08-10 | 2004-03-11 | Altana Pharma Ag | Piperidine-derivatives as pde4 inhibitors |
| CA2494613C (en) | 2002-08-10 | 2011-06-28 | Altana Pharma Ag | Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors |
| HRP20050197A2 (en) | 2002-08-10 | 2006-06-30 | Altana Pharma Ag | Piperidine-n-oxide-derivatives |
| EP1581533A2 (en) | 2002-08-17 | 2005-10-05 | ALTANA Pharma AG | Novel benzonaphthyridines |
| RS20050116A (sr) | 2002-08-17 | 2007-11-15 | Altana Pharma Ag., | Novi fenantridini |
| DE60322713D1 (de) | 2002-08-21 | 2008-09-18 | Boehringer Ingelheim Pharma | Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung |
| SE0202483D0 (sv) | 2002-08-21 | 2002-08-21 | Astrazeneca Ab | Chemical compounds |
| DE60231341D1 (de) | 2002-08-23 | 2009-04-09 | Ranbaxy Lab Ltd | Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten |
| EA011095B1 (ru) | 2002-08-29 | 2008-12-30 | Бёрингер Ингельхайм Фармасьютиклз, Инк. | Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний |
| ATE348616T1 (de) | 2002-08-29 | 2007-01-15 | Altana Pharma Ag | 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer |
| JP4587295B2 (ja) | 2002-08-29 | 2010-11-24 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｐｄｅ４インヒビターとしての３−ヒドロキシ−６−フェニルフェナントリジン |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| JP2006096662A (ja) | 2002-09-18 | 2006-04-13 | Sumitomo Pharmaceut Co Ltd | 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
| PL376154A1 (en) | 2002-09-18 | 2005-12-27 | Ono Pharmaceutical Co, Ltd. | Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient |
| EP1542996A4 (en) | 2002-09-20 | 2009-11-18 | Merck & Co Inc | OCTAHYDRO-2H-NAPHTOc1,2-F INDOL-4-CARBONSUUREAMIDE DERIVATIVES AS SELECTIVE MODULATORS OF THE GLUCOCORTICOID RECEPTOR |
| JP2004107299A (ja) | 2002-09-20 | 2004-04-08 | Japan Energy Corp | 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
| DE10246374A1 (de) | 2002-10-04 | 2004-04-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| CA2499314C (en) | 2002-10-11 | 2010-08-24 | Pfizer Inc. | Indole derivatives as beta-2 agonists |
| EP1440966A1 (en) | 2003-01-10 | 2004-07-28 | Pfizer Limited | Indole derivatives useful for the treatment of diseases |
| ES2291733T3 (es) | 2002-10-22 | 2008-03-01 | Glaxo Group Limited | Compuestos de ariletanolamina medicinales. |
| ATE380185T1 (de) | 2002-10-23 | 2007-12-15 | Glenmark Pharmaceuticals Ltd | Tricyclische verbindungen zur behandlung von entzündlichen- und allergischen erkrankungen: verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen |
| DK1556342T3 (da) | 2002-10-28 | 2008-07-21 | Glaxo Group Ltd | Phenethanolaminderivat til behandling af respiratoriske sygdomme |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| GB0225287D0 (en) | 2002-10-30 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| DE10253426B4 (de) | 2002-11-15 | 2005-09-22 | Elbion Ag | Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung |
| DE10253220A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE10253282A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| DE10261874A1 (de) | 2002-12-20 | 2004-07-08 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| JP4606408B2 (ja) | 2003-01-21 | 2011-01-05 | メルク・シャープ・エンド・ドーム・コーポレイション | 選択的グルココルチコイド受容体調節物質としての１７−カルバモイルオキシコルチゾル誘導体 |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| EP1601657A1 (en) | 2003-03-12 | 2005-12-07 | Vertex Pharmaceuticals Incorporated | Pyrazole modulators of atp-binding cassette transporters |
| EP1460064A1 (en) | 2003-03-14 | 2004-09-22 | Pfizer Limited | Indole-2-carboxamide derivatives useful as beta-2 agonists |
| WO2004110352A2 (en) | 2003-05-16 | 2004-12-23 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-cftr and uses thereof |
| GB0312832D0 (en) | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
| WO2004111014A1 (en) | 2003-06-06 | 2004-12-23 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as modulators of atp-binding cassette transporters |
| CA2528851A1 (en) | 2003-06-10 | 2004-12-16 | Ace Biosciences A/S | Extracellular aspergillus polypeptides |
| KR20060037450A (ko) * | 2003-08-18 | 2006-05-03 | 패리온 사이언스 인코퍼레이티드 | 사이클릭 피라지노일구아니딘 나트륨 채널 차단제 |
| AU2004271945A1 (en) * | 2003-08-18 | 2005-03-24 | Parion Sciences, Inc. | Aliphatic pyrazinoylguanidine sodium channel blockers |
| MXPA06002567A (es) | 2003-09-06 | 2006-09-04 | Vertex Pharma | Moduladores de transportadores con casete de union de atp. |
| RU2006115602A (ru) | 2003-10-08 | 2007-11-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы переносчиков атф-связывающих кассет |
| US7541466B2 (en) | 2003-12-23 | 2009-06-02 | Genzyme Corporation | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases |
| WO2005075435A1 (en) | 2004-01-30 | 2005-08-18 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| CA2569402A1 (en) | 2004-06-04 | 2005-12-22 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-cftr and uses thereof |
| EP1865949B1 (en) | 2005-03-11 | 2012-11-14 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| CA2600869A1 (en) | 2005-03-18 | 2006-09-28 | The Regents Of The University Of California | Compounds having activity in correcting mutant-cftr processing and uses thereof |
| AU2006251624A1 (en) | 2005-05-24 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding cassette transporters |
| US7999113B2 (en) | 2005-08-11 | 2011-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
-
2008
- 2008-05-05 CN CN2008800226814A patent/CN101687851B/zh not_active Expired - Fee Related
- 2008-05-05 AT AT08759419T patent/ATE499363T1/de active
- 2008-05-05 PT PT08759419T patent/PT2155721E/pt unknown
- 2008-05-05 AU AU2008248598A patent/AU2008248598B2/en not_active Ceased
- 2008-05-05 KR KR1020097025395A patent/KR20100005730A/ko not_active Abandoned
- 2008-05-05 BR BRPI0811562-1A2A patent/BRPI0811562A2/pt not_active IP Right Cessation
- 2008-05-05 ES ES08759419T patent/ES2361595T3/es active Active
- 2008-05-05 EP EP11152559A patent/EP2332933A1/en not_active Withdrawn
- 2008-05-05 DE DE602008005140T patent/DE602008005140D1/de active Active
- 2008-05-05 PL PL08759419T patent/PL2155721T3/pl unknown
- 2008-05-05 JP JP2010506915A patent/JP5244904B2/ja not_active Expired - Fee Related
- 2008-05-05 CA CA002685546A patent/CA2685546A1/en not_active Abandoned
- 2008-05-05 EP EP08759419A patent/EP2155721B1/en active Active
- 2008-05-05 PE PE2008000782A patent/PE20090733A1/es not_active Application Discontinuation
- 2008-05-05 US US12/451,152 patent/US8318935B2/en not_active Expired - Fee Related
- 2008-05-05 WO PCT/EP2008/055497 patent/WO2008135557A1/en not_active Ceased
- 2008-05-05 NZ NZ580737A patent/NZ580737A/en not_active IP Right Cessation
- 2008-05-05 EA EA200901489A patent/EA200901489A1/ru unknown
- 2008-05-05 MX MX2009012077A patent/MX2009012077A/es active IP Right Grant
- 2008-05-06 TW TW097116687A patent/TWI351402B/zh not_active IP Right Cessation
- 2008-05-06 AR ARP080101913A patent/AR066458A1/es not_active Application Discontinuation
- 2008-05-06 CL CL2008001301A patent/CL2008001301A1/es unknown
-
2009
- 2009-10-26 ZA ZA200907491A patent/ZA200907491B/xx unknown
- 2009-10-29 IL IL201828A patent/IL201828A0/en unknown
- 2009-11-04 CR CR11091A patent/CR11091A/es unknown
- 2009-11-05 GT GT200900289A patent/GT200900289A/es unknown
- 2009-11-06 SV SV2009003406A patent/SV2009003406A/es active IP Right Grant
- 2009-11-06 CO CO09125992A patent/CO6290667A2/es not_active Application Discontinuation
- 2009-11-06 HN HN2009003214A patent/HN2009003214A/es unknown
- 2009-11-06 EC EC2009009718A patent/ECSP099718A/es unknown
- 2009-11-06 TN TNP2009000469A patent/TN2009000469A1/fr unknown
- 2009-11-30 MA MA32385A patent/MA31400B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066458A1 (es) | Derivados de piperidina, procesos de obtencion y composiciones farmaceuticas. | |
| AR058700A1 (es) | Compuestos heterociclicos como bloqueadores del canal de sodio epitelial | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| AR084388A1 (es) | Compuestos nitrogenados heterociclicos inhibidores de la replicacion del vhc y composiciones farmaceuticas que los contienen | |
| AR060658A1 (es) | Derivados de diceto-piperazina y piperidina como agentes antivirales | |
| AR045938A1 (es) | Peptidos macrociclicos activos contra el virus de la hepatitis c | |
| AR057871A1 (es) | Compuestos que comprenden una lactama o un resto de derivado lactamico procesos para prepararlos y sus usos.composiciones farmaceuticas. | |
| AR062630A1 (es) | Derivados de bipiridina sustituidos y su uso | |
| AR055620A1 (es) | Derivados de cicloalcano-carboxamidas | |
| BR112015015275A2 (pt) | composto heterocíclico substituído por halogênio | |
| CO6251241A2 (es) | Compuestos de prolina modificados con actividad anti-vhc | |
| AR072227A1 (es) | Derivados de triazinona sustituidos | |
| ECSP099335A (es) | Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos | |
| AR053770A1 (es) | Pirimidinas como antagonistas del receptor de prostaglandina d2. composiciones farmaceuticas. | |
| WO2008148849A3 (en) | Piperidine/piperazine derivatives | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| AR064258A1 (es) | Inhibidores macrociclicos del virus de hepatitis c | |
| PE20081362A1 (es) | DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K | |
| AR044152A1 (es) | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad | |
| AR061581A1 (es) | Compuestos de pirro[1,2-b]piridazinona,composiciones farmaceuticas que los contienen y usos para tratar hepatitis c. | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| AR040626A1 (es) | Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy) | |
| AR076235A1 (es) | Compuestos organicos y sus usos | |
| AR067542A1 (es) | Compuestos macrociclicos de indol utiles para el tratamiento de hepatitis c | |
| PE20091433A1 (es) | Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procedimientos para su preparacion 177 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |